Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alirocumab clinical outcomes in coronary heart disease
ChiCTR2200060689Phase 4Recruiting
- Sponsor
- The Second Affiliated Hospital of Soochow University
- Start
- Aug 2022
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of alirocumab and ulinastatin in coronary arteriosclerosis (3 arms), sponsored by The Second Affiliated Hospital of Soochow University. Primary endpoints: Incidence of major adverse cardiovascular events, Total cholesterol and 5 more. Started Aug 2022; status: recruiting.
02
Drugs
alirocumabulinastatin
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR2200060689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060689.